NS-2710
From Wikipedia, the free encyclopedia
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
1-[1-[3-(3-pyridyl)phenyl]benzimidazol-5-yl]ethanone O-ethyloxime
|
|
| Identifiers | |
| PubChem | CID 21310187 |
| Chemical data | |
| Formula | C22H20N4O |
| Molar mass | 356.420 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
| (verify) | |
NS-2710 (LS-193,970) is an anxiolytic drug with a novel chemical structure, developed by the small pharmaceutical company Neurosearch. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic. NS-2710 is a potent but non-selective partial agonist at GABAA receptors, although with little efficacy at the α1 subtype and more at α2 and α3. It has anxiolytic effects comparable to chlordiazepoxide,[1] and while it is a less potent anticonvulsant than the related drug NS-2664, it has a much longer duration of action, and similarly to other α2/α3-preferring partial agonists produces little sedative effects or physical dependence.[2]
References[edit]
- ^ Evenden J, Duncan B, Ko T. A comparison of the effects of psychotomimetics and anxiolytics on punished and unpunished responding maintained by fixed interval schedules of food reinforcement in the rat. Behavioural Pharmacology. 2006 Feb;17(1):87-99. PMID 16377966
- ^ Mirza NR, Nielsen EØ. Do subtype-selective gamma-aminobutyric acid A receptor modulators have a reduced propensity to induce physical dependence in mice? Journal of Pharmacology and Experimental Therapeutics. 2006 Mar;316(3):1378-85. PMID 16352707
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
